Victoza® Prefilled Pen for Type 2 Diabetes

Victoza® Prefilled Pen contains liraglutide, a once-daily GLP-1 receptor agonist used with diet and exercise to improve blood sugar control in adults with type 2 diabetes. Many patients choose US delivery from Canada for access to Canadian pricing, which can help even without insurance, alongside prompt, express, cold-chain shipping.

CanadianInsulin connects patients with licensed Canadian pharmacies. Prescriptions are verified with your clinic before dispensing.

What Victoza® Is and How It Works

Victoza® is a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps lower glucose by enhancing glucose-dependent insulin secretion, suppressing glucagon after meals, slowing gastric emptying, and promoting satiety. In adults with type 2 diabetes, it reduces A1C when added to lifestyle changes and can be used alone or with other diabetes medications. In people with established heart disease and type 2 diabetes, liraglutide has demonstrated cardiovascular risk reduction.

US shipping from Canada is available through CanadianInsulin with secure ordering and cross-border dispensing that follows prescription verification. For practical tips on dose optimization, see the Victoza Dosing Guide.

Who Victoza® Is For

Victoza is indicated for adults with type 2 diabetes to improve glycemic control as an adjunct to diet and exercise. It may be appropriate for individuals who need additional A1C reduction after metformin, or those seeking a non-insulin injectable option. It is not for type 1 diabetes or diabetic ketoacidosis, and it is not approved for weight loss. Do not use if there is a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), or after a serious hypersensitivity to liraglutide or any component. Use caution in patients with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or kidney impairment.

For an overview of related therapies and care categories, browse Type 2 Diabetes and Non Insulin Injectables.

Dosage and Usage

Victoza is taken once daily, at the same time each day, with or without food. A common starting dose is 0.6 mg daily for one week to improve gastrointestinal tolerability. After the first week, many patients advance to 1.2 mg daily. If additional glycemic control is needed, the dose may be increased to 1.8 mg daily. When used with a sulfonylurea or insulin, a healthcare professional may recommend lower doses of those agents to reduce hypoglycemia risk.

General pen steps: attach a new needle, perform the flow check for a new pen per device instructions, select the prescribed dose, choose an injection site (abdomen, thigh, or upper arm), and inject into the subcutaneous tissue. Rotate injection sites to reduce skin irritation. Refer to the device guide and your clinician’s instructions for full technique. For broader pen tips, see Use Insulin Pen.

Strengths and Forms

Victoza is supplied as a prefilled, multidose pen containing 6 mg/mL liraglutide solution that delivers 0.6 mg, 1.2 mg, or 1.8 mg doses. Pack sizes may vary by pharmacy and availability.

Missed Dose and Timing

If a dose is missed, take it as soon as remembered if it is within about 12 hours of the usual time. If more than 12 hours have passed, skip the missed dose and take the next dose at the regular time. Do not take extra doses or two doses on the same day. If several consecutive doses are missed, re-initiation at 0.6 mg may be considered to help reduce gastrointestinal side effects; follow the product label and your prescriber’s plan.

Storage and Travel Basics

Unopened pens should be refrigerated. Do not freeze. After first use, a Victoza pen can typically be kept at room temperature or refrigerated for a limited in-use period as per the product label; protect from heat and light, and never use if previously frozen. When traveling, carry pens, needles, and supplies in your hand luggage with an insulated pouch and cold packs that do not directly touch the pen. Keep the pen cap on when not in use and verify dose settings before each injection.

For travel strategies with GLP-1 medicines, see Travel With Ozempic.

Pen Handling and Sharps Disposal

• Never share a Victoza pen or needles with anyone.
• Use a new, sterile needle for each injection.
• Perform the flow check when starting a new pen as described in the device guide.
• Inject into recommended sites and rotate locations to prevent lipodystrophy.
• Place used needles in an FDA-cleared sharps container or a sturdy, puncture-resistant household container if permitted locally. Follow community regulations for disposal.

Benefits

• Proven A1C reduction when combined with diet and exercise.
• Low risk of hypoglycemia when used without insulin or sulfonylureas.
• Weight neutrality or modest weight loss observed in some patients.
• Cardiovascular benefit in adults with type 2 diabetes and established cardiovascular disease.
• Simple once-daily dosing, independent of meals.

To compare this medicine with other GLP-1 options, read Victoza vs Ozempic.

Side Effects and Safety

• Common: nausea, vomiting, diarrhea, constipation, decreased appetite, indigestion, and injection site reactions.
• Other: headache, fatigue, abdominal pain, dizziness, and mild heartburn.

Serious but less common risks include pancreatitis, gallbladder disease, kidney problems from dehydration, severe gastrointestinal effects, and serious allergic reactions. Liraglutide carries a boxed warning for thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. Avoid use in patients with a personal or family history of MTC or in those with MEN 2. Hypoglycemia can occur, especially when combined with insulin or sulfonylureas. Seek emergency care for symptoms such as severe abdominal pain, persistent vomiting, signs of allergic reaction, or symptoms suggestive of low blood sugar when at risk.

Drug Interactions and Cautions

• Using Victoza with a sulfonylurea or insulin may increase hypoglycemia risk; a prescriber may adjust those doses.
• Do not combine with other GLP-1 receptor agonists.
• Delayed gastric emptying may affect the absorption of certain oral medications; monitor narrow therapeutic index drugs as directed.
• Use caution in patients with a history of pancreatitis, gallstones, severe gastrointestinal disease, or significant renal impairment.
• Discuss pregnancy, breastfeeding, and planned surgeries with a clinician before use.

What to Expect Over Time

Gastrointestinal effects are most common at initiation and often lessen with continued use and stepwise titration. A1C reduction typically appears after sustained daily dosing and lifestyle measures. Some individuals notice reduced appetite, which may support nutritional goals under clinical guidance. Cardiometabolic benefits accrue over time when treatment is maintained alongside diet, activity, and other prescribed therapies.

Compare With Alternatives

Alternative incretin-based therapies include oral semaglutide and dual GIP/GLP-1 agonists. Options we offer include Rybelsus Semaglutide Pills and Mounjaro. Choice should reflect individual goals, tolerability, cardiovascular history, and cost considerations.

Pricing and Access

Many customers use Canadian pricing to lower out-of-pocket costs compared with typical US cash pay. Order refills securely, and choose US delivery from Canada with prompt, express, cold-chain shipping. For potential extra savings, check our promotions.

Availability and Substitutions

Availability can vary. If a specific presentation is unavailable, a prescriber may recommend a suitable alternative in the same class or another antihyperglycemic agent aligned with your treatment plan.

Patient Suitability and Cost-Saving Tips

• May suit adults with type 2 diabetes needing additional A1C lowering after lifestyle measures and first-line therapy.
• Not for type 1 diabetes, DKA, or individuals with MTC or MEN 2.
• Discuss past pancreatitis, gallbladder disease, kidney issues, or severe GI disease before use.
• Consider multi-month supplies if appropriate to reduce per-shipment costs.
• Enroll in refill reminders to prevent gaps in therapy.
• Review education resources like Cost of Victoza for budgeting strategies.

Questions to Ask Your Clinician

• Is Victoza appropriate for my A1C goals and cardiovascular risk profile?
• Should I adjust doses of my insulin or sulfonylurea when starting Victoza?
• How should we manage nausea during titration?
• What signs of pancreatitis or gallbladder disease should prompt evaluation?
• Do any of my oral medications require monitoring due to delayed gastric emptying?
• What lab follow-up schedule should we plan after initiation?

Authoritative Sources

• FDA Prescribing Information
• Novo Nordisk Victoza Prescribing Info
• MedlinePlus Liraglutide

Batteries, needles, and instructions arrive with pharmacy labeling. Temperature-sensitive items ship with cold-chain handling and insulated packaging.

Ready to get started? Securely upload your prescription and complete checkout for US delivery from Canada with prompt, express, cold-chain shipping.

Disclaimer: This information is educational and not a substitute for professional medical advice. Always follow your clinician’s guidance and the approved product label.